Pfizer focus on costs to deliver another $1.5 billion in savings

23 May 2024
pfizer_building_big

A new  cost-cutting campaign from New York-based Pfizer (NYSE: PFE) demonstrates the intensity of the firm’s focus on ensuring operational efficiencies.

The company has already announced a rationalization and “realignment” program, which is in full swing and  on track to deliver around $4 billion in savings by the end of this year.

Pfizer has now said it will engage in a separate, “multi-year program” to reduce the cost of goods sold, targeting operational efficiencies, network structure changes, and product portfolio enhancements.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical